In conclusion, reduced nitric oxide bioactivity contributes to cardiac and vascular remodeling. Nitric-oxide-enhancing therapy can slow cardiac and vascular remodeling. African-Americans with heart failure exhibit nitric oxide deficiency and a dramatic benefit from nitric-oxide-enhancing therapy. The potential benefit of this therapy in other groups with heart failure and in other vascular remodeling disease processes requires further study.
|Original language||English (US)|
|Number of pages||3|
|Journal||Texas Heart Institute Journal|
|State||Published - Sep 23 2005|